Related Experiment Video
Updated: May 28, 2026

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
Published on: December 23, 2016
Self-assembled polypeptide micelles for fungal keratitis treatment
Huayang Feng1, Xiwen Geng1, Hailing Jia1
1Henan Eye Hospital, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, 450003, PR China. lijingguo@zzu.edu.cn.
Abstract:
A self-assembled HDP-mimicking polypeptide micelle was developed for fungal keratitis treatment. The lead polylysine-b-polyleucine diblock polypeptide micelle showed potent activity against Fusarium solani, low cytotoxicity toward human corneal epithelial cells, and therapeutic efficacy comparable to voriconazole in vivo.
Insights
A novel polypeptide micelle effectively treats fungal keratitis. This self-assembled nanoparticle shows potent antifungal activity and safety, offering a promising alternative for eye infections.
Area of Science:
- Ophthalmology
- Nanotechnology
- Biomaterials
Background:
- Fungal keratitis poses a significant threat to vision.
- Current treatments have limitations, necessitating novel therapeutic strategies.
Purpose of the Study:
- To develop and evaluate a self-assembled polypeptide micelle for fungal keratitis treatment.
- To assess the efficacy and safety of the developed micelle against Fusarium solani.
Main Methods:
- Fabrication of a polylysine-b-polyleucine diblock polypeptide micelle.
- In vitro assessment of antifungal activity against Fusarium solani.
- In vitro cytotoxicity evaluation using human corneal epithelial cells.
- In vivo therapeutic efficacy study in a fungal keratitis model.
Main Results:
- The polypeptide micelle demonstrated potent activity against Fusarium solani.
- The micelle exhibited low cytotoxicity toward human corneal epithelial cells.
- In vivo studies showed therapeutic efficacy comparable to voriconazole.
Conclusions:
- Self-assembled polypeptide micelles are a viable strategy for fungal keratitis treatment.
- The developed polylysine-b-polyleucine micelle offers a promising, safe, and effective therapeutic option.
